On June 23, 2026, the Department of Justice announced its largest coordinated health care fraud enforcement action to date, charging 455 defendants, including 90 doctors and other licensed medical professionals, in connection with more than $6.5 billion in alleged false claims. The operation, spanning 56 federal districts and 45 states and territories, with 50 state Medicaid Fraud Control Units participating, marks a structural shift in how the Department enforces health care fraud. Of the 455 defendants charged, 295 are involved in Medicaid fraud, representing the largest number of Medicaid-related defendants and the largest Medicaid loss in the Department’s history, at over $518 million. 

Several cases highlighted in the announcement originated with the Health Care Fraud Unit’s Data Fusion Center and its newly formed Financial Intelligence Review Team, not from whistleblower complaints or audits. For example, one Illinois case involved a $67 million scheme involving fraudulent behavioral health billing. It was identified because a provider allegedly billed for more counseling hours per day than his staff could physically provide, even when staff were scheduled at all available times. Data analysis cross-referenced billing records with hospital admission dates and showed that patients were institutionalized elsewhere on days when services were allegedly rendered. The investigation reportedly opened within five days of the financial intelligence review, and the defendant was arrested less than seven months later while attempting to leave the country. 

This signals a significant shift in how investigations begin. Statistical anomalies were once used to flag claims for post-payment audit, but they now serve as frontline tools. Centers for Medicare & Medicaid Services’ (CMS) parallel announcement that it will possess Fraud Division analytics tools within its Integrated Data Repository, alongside new data-sharing agreements with DHS and FTC, suggests this will accelerate rather than remain a novel approach. 

A closer look shows that amniotic wound allograft billing emerged as a dominant theme, with 11 defendants charged across six districts. The government alleges a pattern in which companies acquired allografts from tissue banks, relabeled them, and marked them up by as much as 2,000%, paying kickbacks to marketers and providers who, in some cases, applied the grafts to hospice patients without physician coordination or clinical justification. One nurse practitioner in the Southern District of Texas is alleged to have billed Medicare an average of more than $1 million per patient in a $906 million scheme. 

This wave comes with regulation. CMS separately reduced the Medicare payment rate for allografts to $127 per square centimeter, effective January 1, 2026, a cut the agency says was necessary to prevent a Part B premium increase. The pairing of the payment correction with criminal charges is a useful pattern to watch, especially for compliance counsel in the medical equipment and biologics markets. More specifically, aggressive reimbursement growth in this niche category appears to trigger both regulatory rate corrections and criminal scrutiny simultaneously. 

Moreover, the criminal charges were accompanied by substantial civil and administrative actions. CMS suspended 1,079 providers and revoked billing privileges for 1,403 more. Additionally, HHS-OIG pursued more than $10 billion in Civil Monetary Penalties Law actions tied to payments intercepted before disbursement. The DEA initiated 928 administrative actions to revoke controlled-substance authority, and separately, 13 defendants face civil health care fraud charges totaling $14.8 million, as well as 31 additional civil settlements totaling $23 million. CMS Administrator Dr. Mehmet Oz described the agency’s posture as no longer “playing catch-up.” This illustrates that providers facing criminal exposure also face civil, administrative, and licensure consequences that proceed on different timelines and under different evidentiary standards.